Production of recombinant proteins in bacteria: The inclusion bodies formation and their use in biomedicine

Recent Patents on Biomedical Engineering

Volumn 3, Issue 3, 2010, Pages 153-161

  Peternel, Špela ^a,b   Liović, Mirjana ^a,b  

^a NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Bacterial cultivation; E. coli; Inclusion bodies; Nanoparticles; Protein aggregation; Recombinant protein production

Indexed keywords

BACTERIOLOGY; ESCHERICHIA COLI; NANOPARTICLES;

BACTERIAL CULTIVATION; E. COLI; INCLUSION BODIES; PROTEIN AGGREGATION; RECOMBINANT PROTEIN PRODUCTIONS;

PROTEINS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI;

EID: 78650949196     PISSN: 18747647     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874764711003030153     Document Type: Article

References (110)

1. Walsh G. Biopharmaceuticals: recent approvals and likely directions. Trends Biotechnol 2005; 23(11): 553-8
2. Itakura K, Hirose T, Crea R, Riggs AD, Heyneker HL, Bolivar F, et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science 1977; 198(4321): 1056-63
3. Johnson IS. Human insulin from recombinant DNA technology. Science 1983; 219(4585): 632-7
4. Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009; 27(3): 297-306
5. Terpe K. Overview of bacterial expression systems for heterologous protein production: from molecular and biochemical fundamentals to commercial systems. Appl Microbiol Biotechnol 2006; 72(2): 211-22
6. Graumann K, Premstaller A. Manufacturing of recombinant therapeutic proteina in microbial systems. Biotechnol J 2006; 2006(1): 164-86
7. Schmidt FR. Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 2004; 65(4): 363-72
8. Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009; 8: 17
9. Walsh G. Biopharmaceutical benchmarks 2006. Nat Biotechnol 2006; 24(7): 769-76
10. Baneyx F. Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 1999; 10(5): 411-21
11. de Groot NS, Espargaro A, Morell M, Ventura S. Studies on bacterial inclusion bodies. Future Microbiol 2008; 3: 423-35
12. Smith A. Protein misfolding. Nature 2003; 426(6968): 883
13. Swartz JR. Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 2001; 12(2): 195-201
14. Eiteman MA, Altman E. Overcoming acetate in Escherichia coli recombinant protein fermentations. Trends Biotechnol 2006; 24(11): 530-6
15. Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol 2004; 22(7): 346-53
16. Rosano GL, Ceccarelli EA. Rare codon content affects the solubility of recombinant proteins in a codon bias-adjusted Escherichia coli strain. Microb Cell Fact 2009; 8: 41
17. Grabherr R, Nilsson E, Striedner G, Bayer K. Stabilizing plasmid copy number to improve recombinant protein production. Biotechnol Bioeng 2002; 77(2): 142-7
18. Hoffmann F, Rinas U. Stress induced by recombinant protein production in Escherichia coli. Adv Biochem Eng Biotechnol 2004; 89: 73-92
19. Peternel S. Designing non-classical inclusion bodies. In: Ortendhal V, Salchow H, Eds. Ribosomal Proteins and Protein Engineering: Design, Selection and Applications. Hauppauge, NY: Nova Science Publishers 2010: pp. 1-20
20. Graumann K, Premstaller A. Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 2006; 2006(1): 164-86
21. Studier FW, Moffatt BA. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol 1986; 189(1): 113-30
22. Grossman TH, Kawasaki ES, Punreddy SR, Osburne MS. Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability. Gene 1998; 209(1-2): 95-103
23. Peternel S, Jevsevar S, Bele M, Gaberc-Porekar V, Menart V. New properties of inclusion bodies with implications for biotechnology. Biotechnol Appl Biochem 2008; 49(Pt 4): 239-46
24. Jevsevar S, Gaberc-Porekar V, Fonda I, Podobnik B, Grdadolnik J, Menart V. Production of nonclassical inclusion bodies from which correctly folded protein can be extracted. Biotechnol Prog 2005; 21(2): 632-9
25. Peternel S, Grdadolnik J, Gaberc-Porekar V, Komel R. Engineering inclusion bodies for non denaturing extraction of functional proteins. Microb Cell Fact 2008; 7: 34
26. Vera A, Gonzalez-Montalban N, Aris A, Villaverde A. The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng 2007; 96(6): 1101-6
27. Stewart, F., Zhang, Y., Buchholz, F. Novel DNA cloning method relying on the E. coli RECE/RECT recombination system. EP1291420 (2003)
28. Candau, R., Donahue, R.A., Seed, J. Simultaneous cloning of genes and expression of recombinant proteins in Escherichia coli. US20070674596 20070213 (2009)
29. Moon-Hee, S., Seung-Goo, L., Seung-Pyo, H., Hwa-Jung, S. Novel promoters and gene expression method by using the promoters. US2007128696 (2007)
30. Wei, Y., Huang, R., Du, L. Constitutive expression promoter in Escherichia coli and applications in Escherichia coli. CN101560516 (2009)
31. Kwon, N.Y., Yoon, L.S., Hong, K.K., Koo, K.S. Novel high constitutive expression promoters isolated from Edwardsiella tarda. KR20090026913 (2009)
32. Takayama, M., Nomura, Y., Kato, I. Low-temperature inducible expression promoter and low-temperature inducible expression vector containing the promoter. JP2006340729 (2006)
33. Lagosky, P. Promoters for gene expression. JP2006187295 (2006)
34. Fischer, M. Expression plasmids regulated by osmB promoter. JP2006068019 (2006)
35. Kopetzki, E., Schantz, C. New Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy. CA2274982 (2000)
36. Martin, F., Cencioni, S., Colagrande, A., Thaller, M.C., D Andrea, M.M., Rossolini, G.M. Novel selection system. WO2007039632 (2007)
37. Scherman, D., Marie, C. Plasmid production and expression of recombinant proteins in cells cultivated without antibiotics. WO2009027351 (2009)
38. Wacker M, Linton D, Hitchen PG, Nita-Lazar M, Haslam SM, North SJ, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002; 298(5599): 1790-3
39. Aebi, M., Wacker, M. System and method for the production of recombinant glycosylated proteins in a prokaryotic host. WO03074687 (2003)
40. Aebi, M., Wacker, M. System and method for the production of recombinant proteins. US2004265954 (2004)
41. Peternel S, Gaberc-Porekar V, Komel R. Bacterial growth conditions affect quality of GFP expressed inside inclusion bodies. Acta Chim Slov 2009; 56(4): 860-7
42. Peternel S, Grdadolnik J, Gaberc-Porekar V, Komel R. Engineering inclusion bodies for non denaturing extraction of functional proteins. Microb Cell Fact 2008; 7: 34
43. Jevsevar S, Palcic J, Jalen S, Pavko A. Influence of the media composition on behavior of the pET expression systems. Acta Chim Slov 2007; 54: 360-5
44. Carbonell X, Corchero JL, Cubarsi R, Vila P, Villaverde A. Control of Escherichia coli growth rate through cell density. Microbiol Res 2002; 157(4): 257-65
45. Yin J, Li G, Ren X, Herrler G. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 2007; 127(3): 335-47
46. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K, et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 2008; 7: 11
47. De Marco A, Vigh L, Diamant S, Goloubinoff P. Native folding of aggregation-prone recombinant proteins in Escherichia coli by osmolytes, plasmid- or benzyl alcohol-overexpressed molecular chaperones. Cell Stress Chaperones 2005; 10(4): 329-39
48. De Marco A, De Macro V. Bacteria co-transformed with recombinant proteins and chaperones cloned in independent plasmids are suitable for expression tuning. J Biotechnol 2004; 109(1-2): 45-52
49. Schrodel A, Volz J, De Marco A. Fusion tags and chaperone coexpression modulate both the solubility and the inclusion body features of the recombinant CLIPB14 serine protease. J Biotechnol 2005; 120(1): 2-10
50. Jaeger, K.E., Eggert, T., Hummel, W., Seidel, A., Rosenau, F. Chaperone toolbox. WO2010012424 (2010)
51. Smith, H.E., Robb, F.T. Improved folding of recombinant proteins via co-expression of archaeal chaperones. WO2010005708 (2010)
52. Scholz, C., Andres, H., Faatz, E., Engel, A., Schmitt, U., Bazarsuren, A, et al. Use of FKBP chaperones as expression tool. US2003096352 (2003)
53. Yang, X. Method for preparing dissolvable high activity recombinant human epidermal growth factor. CN101353659 (2009)
54. Fotadar U, Zaveloff P, Terracio L. Growth of Escherichia coli at elevated temperatures. J Basic Microbiol 2005; 45(5): 403-4
55. Gu, S.L., Yeon, S.K., Ae, M.H. The method for growth of Escherichia coli at high temperature and production of recombinant protein at high temperature KR20090041698 (2009)
56. Mujacic M, Cooper KW, Baneyx F. Cold-inducible cloning vectors for low-temperature protein expression in Escherichia coli: application to the production of a toxic and proteolytically sensitive fusion protein. Gene 1999; 238(2): 325-32
57. Sorensen HP, Mortensen KK. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb Cell Fact 2005; 4(1): 1
58. Weickert MJ, Doherty DH, Best EA, Olins PO. Optimization of heterologous protein production in Escherichia coli. Curr Opin Biotechnol 1996; 7(5): 494-9
59. Menart, V., Gaberc-Porekar, V., Jevsevar, S. Process for the production of a heterologous protein. WO2004/015124 (2004)
60. Garcia-Fruitos E, Aris A, Villaverde A. Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol 2007; 73(1): 289-94
61. de Groot NS, Ventura S. Effect of temperature on protein quality in bacterial inclusion bodies. FEBS Lett 2006; 580(27): 6471-6
62. Rudolph, R., Soehling, B., Malik, A. New fusion protein, useful for preparation of recombinant proteins or peptides, particularly aspartate proteases and proinsulin useful in diagnostics and therapy, includes the ecotin protein and its signal sequence. DE102005050732 (2007)
63. Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev 1996; 60(3): 512-38
64. Schloesser, T., Dasler, T., Pfeiffer-Schwiesow, K. DNA construct and process for the fermentative production of fusion proteins. EP1916305 (2008)
65. Masaru, H., Naokazu, N., Hiroshi, U., Daisuke, M., Kazuya, M. Method for secretory production of human growth hormone. EP0974654 (2000)
66. De La Rosa, A.P.B., Medina, R.E., Ordonez, A.L.G., Paz, M.L.M.T., Balderas, H.V.E., Antonio, L.R. System for expressing and transporting recombinant proteins to the Escherichia coli periplasm using the TAT (twin-arginine translocation) secretion pathway. MXNL06000069 (2008)
67. Satoshi, I. Production of proteins using secretory signal peptides. GB2438952 (2007)
68. Shokri A, Sanden AM, Larsson G. Cell and process design for targeting of recombinant protein into the culture medium of Escherichia coli. Appl Microbiol Biotechnol 2003; 60(6): 654-64
69. Dassler, T., Wich, G. Process for the fermentative production of antibodies. EP1903115 (2008)
70. Dassler, T., Wich, G., Reutter-Maier A. Method for the fermentative production of proteins. EP1905839 (2008)
71. Dassler, T., Wich, G., Schmid, G. Process for the production of proteins by fermentation. EP1903105 (2008)
72. Ami D, Natalello A, Taylor G, Tonon G, Maria DS. Structural analysis of protein inclusion bodies by Fourier transform infrared microspectroscopy. Biochim Biophys Acta 2006; 1764(4): 793-9
73. Garcia-Fruitos E, Gonzalez-Montalban N, Morell M, Vera A, Ferraz RM, Aris A, et al. Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact 2005; 4: 27
74. Garcia-Fruitos E, Villaverde A. Friendly production of bacterial inclusion bodies. Korean J Chem Eng 2010; 27(2): 385-9
75. Ventura S, Villaverde A. Protein quality in bacterial inclusion bodies. Trends Biotechnol 2006; 24(4): 179-85
76. Smith HE. The transcriptional response of Escherichia coli to recombinant protein insolubility. J Struct Funct Genomics 2007; 8(1): 27-35
77. Villaverde A, Carrio MM. Protein aggregation in recombinant bacteria: biological role of inclusion bodies. Biotechnol Lett 2003; 25(17): 1385-95
78. Garcia-Fruitos E, Rodriguez-Carmona E, Díez-Gil C, Ferraz RM, Vazquez E, Corchero JL, et al. Surface cell growth engineering assisted by a novel bacterial nanomaterial. Adv Mater 2009; 21: 4249-53
79. Garcia-Fruitos E, Seras-Franzoso J, Vazquez E, Villaverde A. Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology 2010; 21(20): 205101
80. Peternel S, Bele M, Gaberc-Porekar V, Komel R. Contraction of inclusion bodies with implications in biotechnology. Acta Chim Slov 2008; 55(3): 608-12
81. Levine, M. Mutants of lysine decarboxylase, vaccines for periodontitis, and methods of use. WO/2009/076226 (2007)
82. Plucienniczak, A., Kesik, M., Porebska, A., Wedrychowicz, H., Jedlina-Panasiuk, L. Inclusion bodies for the oral vaccination of animals. WO/2004/058816 (2003)
83. Kuzyk, M.A., Kay, W.W., Thornton, J.C., Burian, J. Vaccines and agents for inducing immunity in fish against rickettsial diseases, and associated preventative therapy. CA2339327 (2002)
84. Royt, P. Use of pseudan and pseudan inclusion bodies. WO2007008769 (2007)
85. Harrison ST. Bacterial cell disruption: a key unit operation in the recovery of intracellular products. Biotechnol Adv 1991; 9(2): 217-40
86. Stathopulos PB, Scholz GA, Hwang YM, Rumfeldt JA, Lepock JR, Meiering EM. Sonication of proteins causes formation of aggregates that resemble amyloid. Protein Sci 2004; 13(11): 3017-27
87. Riesz P, Kondo T. Free radical formation induced by ultrasound and its biological implications. Free Radic Biol Med 1992; 13(3): 247-70
88. Peternel S, Komel R. Isolation of biologically active nanomaterial (inclusion bodies) from bacterial cells. Microb Cell Fact 2010; 9: 66
89. Cordes RM, Sims WB, Glatz CE. Precipitation of nucleic acids with poly(ethyleneimine). Biotechnol Prog 1990; 6(4): 283-5
90. Wu, L.J. Preparing technique for rapid extraction of antigastrin release tumor vaccine. CN101015687 (2007)
91. Wong HH, Oneill BK, Middelberg APJ. Centrifugal processing of cell debris and inclusion bodies from recombinant Escherichia coli. Bioseparation 1996; 6(6): 361-72
92. Novak S, Maver U, Peternel S, Venturini P, Gaberscek M. Electrophoretic deposition as a tool for separation of protein inclusion bodies from host bacteria in suspension. Colloids Surf A: Physicochem Eng Asp 2009; 340: 155-60
93. Patra AK, Mukhopadhyay R, Mukhija R, Krishnan A, Garg LC, Panda AK. Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli. Protein Expr Purif 2000; 18(2): 182-92
94. Cabrita LD, Bottomley SP. Protein expression and refolding - A practical guide to getting the most out of inclusion bodies. Biotechnol Annu Rev 2004; 10: 31-50
95. Jungbauer A, Kaar W. Current status of technical protein refolding. J Biotechnol 2007; 128(3): 587-96
96. Rudolph R. Successful Protein Folding on an Industrial Scale. In: Cleland JL, Craik CS, Eds. Protein Engineering: Principles and Practice. New York: Wiley-Liss, Inc., 1996: 283-98
97. Fabian H, Mäntele W. Infrared Spectroscopy of Proteins. In: Chalmers JM, Griffiths PR, Eds. Handbook of vibrational spectroscopy: Applications in Life. Pharmaceutical and Natural Sciences. Wiley 2001: 3399-425
98. Middelberg AP. Preparative protein refolding. Trends Biotechnol 2002; 20(10): 437-43
99. Prakash S, Matouschek A. Protein unfolding in the cell. Trends Biochem Sci 2004; 29(11): 593-600
100. Singh SM, Panda AK. Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng 2005; 99(4): 303-10
101. Tsumoto K, Umetsu M, Kumagai I, Ejima D, Arakawa T. Solubilization of active green fluorescent protein from insoluble particles by guanidine and arginine. Biochem Biophys Res Commun 2003; 312(4): 1383-6
102. Umetsu M, Tsumoto K, Nitta S, Adschiri T, Ejima D, Arakawa T, et al. Nondenaturing solubilization of beta2 microglobulin from inclusion bodies by L-arginine. Biochem Biophys Res Commun 2005; 328(1): 189-97
103. Umetsu M, Tsumoto K, Ashish K, Nitta S, Tanaka Y, Adschiri T, et al. Structural characteristics and refolding of in vivo aggregated hyperthermophilic archaeon proteins. FEBS Lett 2004; 557(1-3): 49-56
104. Panda, A.K., Singh, M.S., Upadhyay, K.A. Process for obtaining bioactive recombinant protein from inclusion bodies. EP2147093 (2010)
105. Blaschke, U.K., Dietrich, A., Janowski, B., Schaffner, J. Process for recovering biologically active human G-CSF from inclusion bodies. SI1630173 (2010)
106. Swietnicki W. Folding aggregated proteins into functionally active forms. Curr Opin Biotechnol 2006; 17(4): 367-72
107. Randolph, T.W., Carpenter, J.F., St John, R. High pressure refolding of protein aggregates and inclusion bodies. US2006188970 (2006)
108. Porekar, G.V., Menart, V. Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor. WO 03/051922 (2003)
109. Plucienniczak, A., Saczynska, V., Porebska, A., Szewczyk, B., Ficinska, J. Inclusion bodies as antigens for the oral vaccination of animals. WO2004058806 (2004)
110. Diez-Gil C, Krabbenborg S, Garcia-Fruitos E, Vazquez E, Rodriguez- Carmona E, Ratera I, et al. The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 2010; 31(22): 5805-12